1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Danaher Corporation

Danaher Corporation

DAP.DE
Danaher CorporationDE flagDeutsche Börse
168.55
EUR
-4.00
- -
119.29BMarket Cap
Danaher Corporation
DAP.DE
(Deutsche Börse)

Recent

price

168.55

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
19.21
23.8
26.33
26.27
18.32
20.68
24.42
22.3
24.33
25.05
31.55
34.71
36.74
32.44
32.66
34.47
34.87
Revenue per Share
2.74
3.21
3.45
3.87
3.7
4.81
3.69
3.58
3.78
4.11
4.97
8.77
9.8
6.44
5.33
5.07
5.19
Basic EPS, GAAP
2.9
3.39
4.26
4.38
4.69
4.71
4.24
4.18
4.91
4.64
7.67
9.96
10.21
7.85
7.24
7.38
7.45
Free Cash Flow per Basic Share
0.08
0.09
0.12
0.07
0.32
0.51
1.28
0.54
0.62
1.05
0.87
1.04
1.13
1.69
1.05
1.23
1.28
Dividend per Share
16.77
19.32
22.19
25.88
28.95
30.11
29.96
32.79
35.93
33.81
38.47
45.95
54.08
55.78
60.46
65.81
67.05
Book Value per Share
-0.47
-4.94
-3.93
0.24
1.02
-11.17
-18.18
-15
-6.62
-5.29
-28.59
-30.95
-11.96
-12.04
-13.02
-11.82
-9.81
Tangible Book Value per Share
653
676
693
696
702
698
691
696
701
715
706
715
725
736
731
713
711
Basic Weighted Avg Shares
12,550
16,090
18,260
18,283
12,867
14,434
16,882
15,519
17,049
17,911
22,284
24,802
26,643
23,890
23,875
24,568
24,778
Sales/Revenue/Turnover
16.15
15.85
16.95
17.07
15.89
14.98
16.2
16.58
17.92
18.25
18.99
25.75
28.29
21.77
20.37
19.09
19.21
Operating Margin (%)
388
635
840
851
718
881
1,128
1,117
1,178
1,189
1,775
2,062
2,132
2,166
2,352
2,447
2,483
Depreciation Expense
1,793
2,172
2,392
2,695
2,598
3,357
2,554
2,492
2,651
3,008
3,646
6,433
7,209
4,764
3,899
3,614
3,689
Net Income, GAAP
22.94
20.94
23.63
24.17
21.45
14.35
17.54
14.59
18.77
26.41
18.89
16.34
11.45
16.32
16.08
14.95
15.3
Effective Tax Rate (%)
14.29
13.5
13.1
14.74
20.19
23.26
15.13
16.06
15.55
16.79
16.36
25.94
27.06
19.94
16.33
14.71
14.89
Profit Margin (%)
2,425
2,100
3,382
4,586
4,035
1,666
-209
2,058
2,252
20,664
6,400
3,508
7,494
5,663
2,699
5,949
6,475
Working Capital
2,784
5,207
5,288
3,437
3,402
12,025
9,674
10,327
9,688
22,156
21,978
23,057
19,858
17,661
16,468
19,495
17,561
LT Debt
13,773
16,972
19,084
22,451
23,450
23,764
23,077
26,368
28,227
30,282
39,777
45,177
50,090
53,490
49,550
52,541
52,957
Total Equity
10.02
10.34
10.08
9.36
6.01
5.76
6.23
6.04
6.59
5.27
5.95
8.13
9.52
6.02
5.8
5.71
5.82
Return on Invested Capital (%)
14.5
14.15
12.81
13.22
11.76
12.02
8.07
7.87
8.09
7.42
7.67
11.83
12.23
8.19
6.78
6
6.12
Return on Capital (%)
17.79
18.09
16.82
16.14
13.55
16.24
12.24
11.45
11.05
11.92
13.67
20.9
19.72
11.81
9.14
7.93
7.97
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
23
201
923
LT Borrowings
16,833
18,416
17,561
LT Finance Leases
- -
1,079
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
706
707
708
Market Capitalization
137,419
164,110
133,795

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
9,606
12,756
13,935
Cash, Cash Equivalents & STI
1,528
4,615
5,701
Accounts Receivable, Net
3,755
3,913
3,819
Inventories
2,674
2,489
2,608
Total Current Liabilities
6,324
6,807
7,460
Payables & Accruals
6,301
2,451
6,537
ST Debt
23
201
923
Deferred Revenue
- -
1,353
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.7%
5.98%
6.04%
Free Cash Flow
7.08%
0.88%
-0.68%
Net Income, GAAP
4.38%
5.82%
-7.31%
Sales/Revenue/Turnover
5.95%
2.25%
2.9%
Total Cash Common Dividend
22.81%
18.62%
14.32%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,796
5,743
5,798
6,538
23,875
2025
5,741
5,936
6,053
6,838
24,568
2026
5,951
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.47
1.23
1.13
1.5
5.33
2025
1.33
0.77
- -
1.69
5.07
2026
1.45
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.27
0.27
0.27
1.05
2025
0.27
0.32
- -
0.32
1.23
2026
0.32
- -
- -
- -
- -
Similar Companies
Thermo Fisher Scientific Inc. (TMO.NE)
MDxHealth S.A. (MDXH)
Sona Nanotech Inc. (SNANF)
Dirui Industrial Co.,Ltd. (300396.SZ)
Immunovia AB (IMMNOV.ST)
Arrayit Corporation (ARYC)
Business
Danaher Corporation (NYSE: DHR; DAP.DE), headquartered in Washington, D.C., and founded in 1984 by brothers Steven Rales and Mitchell Rales, operates as a leading global life sciences and diagnostics innovator that accelerates science and technology to improve human health. The company conducts business through three primary segments: Biotechnology (28% of 2024 revenues), which develops therapeutics, genomic medicines, bioprocessing solutions including chromatography, filtration, single-use technologies from subsidiaries such as Cytiva and Pall Corporation, plasmid DNA, mRNA, proteins, and gene therapy tools from Aldevron; Life Sciences (31% of 2024 revenues), offering mass spectrometers, flow cytometry, genomics consumables, lab automation, centrifugation, microscopes, particle characterization, proteomic research reagents from Abcam, and genomic products from Integrated DNA Technologies; and Diagnostics (41% of 2024 revenues), providing instruments, consumables, software, services for disease diagnosis including molecular diagnostics for infectious diseases and cancer from Cepheid, clinical diagnostics and life sciences automation from Beckman Coulter Diagnostics, immunohistochemistry, PCR, immunoassay capabilities, flu detection kits, and digital imaging systems. Danaher serves pharmaceutical companies, biotech firms, research institutions, biopharmaceutical manufacturers, municipal water treatment plants, industrial facilities, dental professionals, hospitals, and healthcare systems worldwide across more than 60 countries, employing approximately 63,000 associates and generating $24 billion in revenue through its Danaher Business System emphasizing continuous improvement, lean manufacturing, and strategic growth. Recent developments include the spinoff of its Environmental & Applied Solutions segment into Veralto, sharpening focus on life sciences and diagnostics; acquisition of Abcam in August 2023 for $5.7 billion to enhance proteomic research consumables; establishment of two new Centers of Innovation in diagnostics in 2024 to accelerate precision medicine with capabilities from Cepheid, Beckman Coulter Diagnostics, and Leica Biosystems; launch of a collaborative research center for CRISPR-based gene-editing therapies targeting rare diseases; a January 2025 investment partnership with Innovaccer Inc. via Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics, unified patient records, and value-based care; and a May 2025 diagnostic development and commercialization partnership with AstraZeneca to scale precision medicine including next-generation AI-powered diagnostics.